β2-agonist and anticholinergic drugs in the treatment of lung disease

Becky J. Proskocil, Allison Fryer

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The lungs are innervated by both the sympathetic and parasympathetic nervous systems, which entails the activation of adrenergic and muscarinic receptors, respectively. Both the adrenergic and muscarinic receptors are G-protein-coupled receptors, and they share many similar signal transduction molecules. These receptors are widely expressed in the lung and the specific receptor expression can vary among the species. The location and the subtype of receptor expressed are important in the regulation of normal airway function. Acetylcholine released from the parasympathetic fibers activates the M3 muscarinic receptors located on the airway smooth muscle, causing bronchoconstriction. To counter this activity, M2 muscarinic receptors located on the parasympathetic nerves inhibit release of acetylcholine. β2-Adrenergic receptors are expressed on the airway smooth muscle where activation causes bronchodilation. Adrenergic receptors are also on the autonomic nerves where they can modulate neurotransmitter release. The crosstalk between these G-protein-coupled receptors and downstream pathways ensures normal airway function. The prejunctional and postjunctional muscarinic and adrenergic receptors control autonomic tone and any imbalance or selective blockade of the receptors can compromise the system and cause the airways to become hyperreactive. The location, function, and crosstalk of the adrenergic and muscarinic receptors must be considered in the design, development, and use of drugs to combat airway diseases.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalProceedings of the American Thoracic Society
Volume2
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Cholinergic Antagonists
Adrenergic Receptors
Lung Diseases
Muscarinic Receptors
Pharmaceutical Preparations
G-Protein-Coupled Receptors
Acetylcholine
Smooth Muscle
Muscarinic M3 Receptors
Parasympathetic Nervous System
Muscarinic M2 Receptors
Autonomic Pathways
Lung
Bronchoconstriction
Sympathetic Nervous System
Neurotransmitter Agents
Signal Transduction

Keywords

  • Acetylcholine
  • Adrenergic receptors
  • Asthma
  • Muscarinic receptors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology
  • Cell Biology

Cite this

β2-agonist and anticholinergic drugs in the treatment of lung disease. / Proskocil, Becky J.; Fryer, Allison.

In: Proceedings of the American Thoracic Society, Vol. 2, No. 4, 2005, p. 305-310.

Research output: Contribution to journalArticle

@article{b3ebdfe25bdf4a4da5d6a28df6a78483,
title = "β2-agonist and anticholinergic drugs in the treatment of lung disease",
abstract = "The lungs are innervated by both the sympathetic and parasympathetic nervous systems, which entails the activation of adrenergic and muscarinic receptors, respectively. Both the adrenergic and muscarinic receptors are G-protein-coupled receptors, and they share many similar signal transduction molecules. These receptors are widely expressed in the lung and the specific receptor expression can vary among the species. The location and the subtype of receptor expressed are important in the regulation of normal airway function. Acetylcholine released from the parasympathetic fibers activates the M3 muscarinic receptors located on the airway smooth muscle, causing bronchoconstriction. To counter this activity, M2 muscarinic receptors located on the parasympathetic nerves inhibit release of acetylcholine. β2-Adrenergic receptors are expressed on the airway smooth muscle where activation causes bronchodilation. Adrenergic receptors are also on the autonomic nerves where they can modulate neurotransmitter release. The crosstalk between these G-protein-coupled receptors and downstream pathways ensures normal airway function. The prejunctional and postjunctional muscarinic and adrenergic receptors control autonomic tone and any imbalance or selective blockade of the receptors can compromise the system and cause the airways to become hyperreactive. The location, function, and crosstalk of the adrenergic and muscarinic receptors must be considered in the design, development, and use of drugs to combat airway diseases.",
keywords = "Acetylcholine, Adrenergic receptors, Asthma, Muscarinic receptors",
author = "Proskocil, {Becky J.} and Allison Fryer",
year = "2005",
doi = "10.1513/pats.200504-038SR",
language = "English (US)",
volume = "2",
pages = "305--310",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - β2-agonist and anticholinergic drugs in the treatment of lung disease

AU - Proskocil, Becky J.

AU - Fryer, Allison

PY - 2005

Y1 - 2005

N2 - The lungs are innervated by both the sympathetic and parasympathetic nervous systems, which entails the activation of adrenergic and muscarinic receptors, respectively. Both the adrenergic and muscarinic receptors are G-protein-coupled receptors, and they share many similar signal transduction molecules. These receptors are widely expressed in the lung and the specific receptor expression can vary among the species. The location and the subtype of receptor expressed are important in the regulation of normal airway function. Acetylcholine released from the parasympathetic fibers activates the M3 muscarinic receptors located on the airway smooth muscle, causing bronchoconstriction. To counter this activity, M2 muscarinic receptors located on the parasympathetic nerves inhibit release of acetylcholine. β2-Adrenergic receptors are expressed on the airway smooth muscle where activation causes bronchodilation. Adrenergic receptors are also on the autonomic nerves where they can modulate neurotransmitter release. The crosstalk between these G-protein-coupled receptors and downstream pathways ensures normal airway function. The prejunctional and postjunctional muscarinic and adrenergic receptors control autonomic tone and any imbalance or selective blockade of the receptors can compromise the system and cause the airways to become hyperreactive. The location, function, and crosstalk of the adrenergic and muscarinic receptors must be considered in the design, development, and use of drugs to combat airway diseases.

AB - The lungs are innervated by both the sympathetic and parasympathetic nervous systems, which entails the activation of adrenergic and muscarinic receptors, respectively. Both the adrenergic and muscarinic receptors are G-protein-coupled receptors, and they share many similar signal transduction molecules. These receptors are widely expressed in the lung and the specific receptor expression can vary among the species. The location and the subtype of receptor expressed are important in the regulation of normal airway function. Acetylcholine released from the parasympathetic fibers activates the M3 muscarinic receptors located on the airway smooth muscle, causing bronchoconstriction. To counter this activity, M2 muscarinic receptors located on the parasympathetic nerves inhibit release of acetylcholine. β2-Adrenergic receptors are expressed on the airway smooth muscle where activation causes bronchodilation. Adrenergic receptors are also on the autonomic nerves where they can modulate neurotransmitter release. The crosstalk between these G-protein-coupled receptors and downstream pathways ensures normal airway function. The prejunctional and postjunctional muscarinic and adrenergic receptors control autonomic tone and any imbalance or selective blockade of the receptors can compromise the system and cause the airways to become hyperreactive. The location, function, and crosstalk of the adrenergic and muscarinic receptors must be considered in the design, development, and use of drugs to combat airway diseases.

KW - Acetylcholine

KW - Adrenergic receptors

KW - Asthma

KW - Muscarinic receptors

UR - http://www.scopus.com/inward/record.url?scp=27644482811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644482811&partnerID=8YFLogxK

U2 - 10.1513/pats.200504-038SR

DO - 10.1513/pats.200504-038SR

M3 - Article

C2 - 16267353

AN - SCOPUS:27644482811

VL - 2

SP - 305

EP - 310

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 4

ER -